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Background: The American Society of Echocardiography (ASE) and European Association of Echocardiogra-
phy (EAE) recommend the use of quantitative estimation of left ventricular (LV) mass and defined partition
values for mild, moderate, and severe hypertrophy. However, the prognostic implications associated with
this categorization are unknown.Methods: In this observational cohort study of unselected adults undergoing echocardiography for any indi-
cation, LV hypertrophy was assessed using the ASE/EAE-recommended formula and measurement conven-
tion from LV linear dimensions indexed to body surface area. Mortality and incident hospitalizations for
cardiovascular disease were the outcomes of this study.Results: Of 2,545 subjects (mean age, 61.9 6 15.8 years; 56.3% women), 52.9% had normal LV mass, and
15.4% had mild, 12.1% moderate, and 19.6% severe LV hypertrophy. During a mean follow-up period of
2.56 1.2 years, 121 deaths and 292 incident hospitalizations for cardiovascular disease occurred. In multivar-
iate models including age, gender, LV ejection fraction, wall motion score index, significant valvular disease,
and atrial fibrillation, the adjusted hazard ratios for death were 1.81 (95% confidence interval [CI], 1.03–3.20;
P = .041) for mild, 2.31 (95% CI, 1.33–4.01; P = .003) for moderate, and 2.30 (95% CI, 1.39–3.79, P = .001) for
severe LV hypertrophy. The adjusted hazard ratios for incident cardiovascular hospitalizations were 1.24 (95%
CI, 0.84–1.82; P = .277) for mild, 2.02 (95% CI, 1.42–2.88; P = .0001) for moderate, and 2.38 (95% CI, 1.75–
3.22, P < .0001) for severe LV hypertrophy. After adjustment for known risk predictors, there was a 1.3-fold
risk for death and cardiovascular disease events per category of LV mass (P = .001).Conclusions: In a cohort study of unselected adult outpatients, the categorization of LV mass according to the
ASE/EAE recommendations offered prognostic information independently of age, gender, and other known
predictors. (J Am Soc Echocardiogr 2011;24:1383-91.)
Keywords: Left ventricular hypertrophy, Left ventricular mass, Death, Echocardiography, PrognosisEchocardiographically detected left ventricular (LV) hypertrophy has
been shown to be a strong independent marker of cardiovascular
risk both in the general population1-4 and in high-risk groups.5-9
Nonetheless, these studies have used a variety of indexation
methods and partition values.
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echo.2011.08.012chamber quantification10 conclude that LV mass from the
ASE-recommended formula using LV linear dimensions indexed
to body surface area (BSA) is preferred in the diagnosis of LV hyper-
trophy over linear measurements such as septal or posterior wall
thickness. In addition, they propose sex-specific cutoff values to
categorize the degree of LV hypertrophy as mild, moderate, and
severe on the basis of the distribution of LV mass in relation to
reference limits in an ethnically heterogeneous North American
population.11
However, despite the widespread use of such descriptive terms in
clinical practice, this categorization is, at present, inadequately substan-
tiated by scientific data, underscoring the weaknesses inherent the use
of arbitrary dichotomous threshold without providing insights into
risks associated with different levels of LV mass. Therefore, aim of
this study was to examine the prognostic implications of the ASE/
EAE partition values of LV mass in a large group of unselected outpa-
tients referred to a tertiary care echocardiography laboratory.1383
Abbreviations
BSA = Body surface area
CI = Confidence interval
HR = Hazard ratio
IVST = End-diastolic
interventricular septal
thickness
LV = Left ventricular
LVIDD = End-diastolic left
ventricular internal dimension
PWT = End-diastolic
posterior wall thickness
RWT = Relative wall
thickness
2D = Two-dimensional
WMSI = Wall motion score
index
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The study population comprised
unselected elective adult outpa-
tients who underwent standard
Doppler echocardiography for
any indication in the period from
January 2005 to March 2009 at
the echocardiography laboratory
of Modena University Hospital.
Criteria for enrollment were (1)
age $ 18 years; (2) complete
resting two-dimensional (2D)
echocardiographic assessment, in-
cluding real-time measurement of
LV mass; and (3) residency in the
province of Modena, Italy. For
patients undergoing more than
one echocardiographic exam
during the aforementioned time
frame,we consideredonly the first
access to the echocardiography
laboratory.Echocardiographic Data
All exams were performed using an Acuson Sequoia ultrasound sys-
tem (Siemens Medical Solutions USA, Inc., Mountain View, CA) and
were performed and/or supervised by cardiologists fully trained in
echocardiography with long-standing experience with the technique
and intense hands-on training period with interpretation of >750
studies.12
LV diameters as well as septal and posterior wall thickness were
measured using the 2D-guided M-mode method in the short-axis
view or the linear 2D method in the parasternal long-axis view. LV
end-diastolic dimensions were measured at the onset of the QRS
complex. LV ejection fraction was assessed using the biplane
Simpson method or the Quinones method using LV end-systolic
and end-diastolic diameters13 or visually estimated, a method that
was documented to have accuracy comparable with that of the other
methods in assessing LV ejection fraction.14
Regional LV systolic function was assessed using a standard
16-segment model.10 Segmental scores were assigned as follows:
1 = normal or hyperkinesis, 2 = hypokinesis, 3 = akinesis, 4 = dyski-
nesis, and 5 = aneurysmal. The wall motion score index (WMSI) was
derived as the sum of all scores divided by the number of segments
visualized. Individual echocardiographic Doppler parameters (mitral
inflow pattern, tissue Doppler, and Valsalva maneuver when neces-
sary) were integrated to grade diastolic function in four stages: normal
diastolic function; impaired relaxation with normal or near normal fill-
ing pressures (grade I/IV); impaired relaxation with moderate eleva-
tion of filling pressures, pseudonormal filling (grade II/IV); and
impaired relaxation with marked elevation of filling pressures, restric-
tive filling (grades III–IV/IV), as previously described.15,16
Left atrial volume was assessed using the modified biplane
Simpson method from apical four-chamber and two-chamber views
and indexed to BSA. Measurements were obtained in end-systole
from the frame preceding mitral valve opening.17,18
Each value represented the average of three consecutive beats.
Significant left-sided valve disease severity was defined as the pres-
ence of aortic or mitral prosthesis or the presence of greater thanmoderate native mitral or aortic valve stenosis or insufficiency, simi-
larly to previous reports.19 Valve disease severity was defined accord-
ing to the American Heart Association and American College of
Cardiology guidelines for the management of valvular heart dis-
ease.20 Applying these guidelines, the cardiologist performing the
exam graded valve disease as absent, mild, moderate, or severe,
and this information was embedded in the echocardiographic report.
The methods used included pulsed-wave and continuous-wave
Doppler velocities and gradients, direct measurement of valve area
planimetry, continuity equation, color Doppler to assess the jet width,
or proximal isovelocity surface area for quantitative evaluation. The
methods used to classify valve disease severity were at the discretion
of the physician performing the exam, and often the final judgment
was based on the combination of more than one method.
All measurements were performed online and entered in an elec-
tronic database at the time of the echocardiographic study. No mod-
ification from the original database was applied, and nomeasurement
was made offline. Hence, the study consisted of a retrospective anal-
ysis of data entered in the electronic echocardiographic database.
LV Mass
LV mass was obtained using the ASE-recommended formula for the
estimation of LVmass from LV linear dimensions on the basis of mod-
eling the left ventricle as a prolate ellipse of revolution: LV mass (g) =
0.8[1.04(LVIDD+ IVST + PWT)3 LVIDD3] + 0.6, where LVIDD is
LV internal end-diastolic dimension, IVST is end-diastolic interventric-
ular septal wall thickness, and PWT is end-diastolic LV posterior wall
thickness.21
LV mass was indexed to BSA. LV mass was also indexed to height
and to height2.7.
Cutoff Limits for LV Hypertrophy
TheASE/EAE guidelines suggest the following cutoffs for LVhypertro-
phy: LV mass/BSA > 95 g/m2 (LV mass/height > 99 g/m, LV mass/
height2.7 > 44 g/m2.7) for women and LV mass/BSA > 115 g/m2
(LV mass/height > 126 g/m, LV mass/height2.7 > 48 g/m2.7) for
men. Values for mild LV hypertrophy are LV mass/BSA of 96 to
108 g/m2 (LV mass/height, 100–115 g/m; LV mass/height2.7, 45–
51 g/m2.7) for women and LV mass/BSA of 116 to 131 g/m2 (LV
mass/height, 127–144 g/m; LV mass/height2.7, 49–55 g/m2.7) for
men; values for moderate LV hypertrophy are LV mass/BSA of 109
to 121 g/m2 (LV mass/height, 116–128 g/m; LV mass/height2.7, 52–
58 g/m2.7) for women and LV mass/BSA of 132 to 148 g/m2 (LV
mass/height, 145–162 g/m; LV mass/height2.7, 56–63 g/m2.7) for
men; values for severe LV hypertrophy are LV mass/BSA
$122 g/m2 for women (LV mass/height $ 129 g/m, LV mass/
height2.7$59g/m2.7) andLVmass/BSA$149g/m2 (LVmass/height
$ 163 g/m, LV mass/height2.7 $ 64 g/m2.7) for men.10LV Geometry
Relative wall thickness (RWT) was measured using the formula (2 
PWT)/LVIDD, which permitted the categorization of an increase in
LV mass as either concentric (RWT $ 0.42) or eccentric (RWT <
0.42) hypertrophy10 and allowed the identification of concentric
remodeling (normal LV mass with increased RWT).Clinical Data
Age, sex, height, weight, BSA, body mass index, and cardiac rhythm
were recorded at the time of echocardiography. History of
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ST-segment elevation myocardial infarction and unstable angina or
non–ST-segment elevation myocardial infarction, history of chronic
coronary artery disease, prior acute or chronic heart failure, and prior
stroke) was obtained using the hospital discharge codes of the public
hospitals of Modena province. Risk factors were obtained retrospec-
tively by manual review of electronic clinical notes of the public hos-
pitals of the province. These electronic records allow assessment of
outpatient visits as well as hospital discharge notes. To collect informa-
tion on medications, we combined two methods: (1) we retrospec-
tively reviewed through the electronic databases of Modena
province public hospital discharge letters and ambulatory cardiology
visits, and (2) we used the Emilia Romagna regional pharmacy central-
ized electronic database. This electronic database contains all
prescriptions that are filled in all pharmacies of the region by all
residents, regardless of the physician prescribing the medication. We
examined all prescriptions filled from 60 days before to 30 days after
the date of the exam.Follow-Up
Themain end point was all-cause death. The secondary end point was
cardiovascular morbidity, measured as the cumulative incidence of
hospitalizations for cardiovascular disease. Included were hospitaliza-
tions for coronary disease, heart failure, ventricular arrhythmias, atrial
fibrillation, lower limb critical ischemia, and stroke or transient
ischemic attack. The diagnoses were derived from hospital discharge
codes. In most cases, more than one code was reported, but only the
first was considered to classify the cause of hospitalizations.
Follow-up information for death was obtained from the national
death index, in which the status of all citizens is constantly updated
and is 100% complete. In Italy, it is mandatory by law that all deceased
patients be immediately registered in this national data bank.
Cardiovascular morbidity requiring hospitalization was assessed using
the electronic archives of the health service of Modena province. All
public hospitalization records of citizens resident in Modena province
are stored in a digital format and may be accessed online after obtain-
ing permission and an access password. This archive allows nearly
complete knowledge of all clinical events requiring hospitalization
in Modena province since 1999. Each electronic record includes up
to 30 to 50 codes reflecting various diagnoses, complications, and
procedures performed while patients were hospitalized. The diagno-
ses were classified according to the International Classification of
Disease, Ninth Revision, Clinical Modification. We obtained comput-
erized records of all incident hospitalizations for cardiovascular rea-
sons as the principal diagnosis after the index echocardiographic
study. In case of uncertainty in adjudicating events from this electronic
database, the general practitioners were contacted by telephone. To
ensure completeness of follow-up, only residents inModena province
were included in the study.Statistical Analysis
Data are shown as percentages for categorical variables and as mean
6 SD for continuous variables. Comparisons across groups were
made using c2 tests for categorical variables and analysis of variance
for continuous variables or Kruskal-Wallis tests for highly skewed
variables.
Kaplan-Meier curves were constructed to show survival and the
cumulative incidence of hospitalizations for cardiovascular diseases
between patients with and without LV hypertrophy and across theLV mass partition values. Event rates 6 1 SE were estimated accord-
ing to the Kaplan-Meier method, and groups were compared using
a two-sided log-rank test for trend across the categories of LV mass.
Univariate and multivariate Cox regression analyses were used to
estimate the relative risk for death and cardiovascular morbidity; these
relative risks are presented as hazard ratios (HRs) with 95% confi-
dence intervals (CIs). Patients were censored at the end of their event
free follow-up. Only the first incident event was included for each
patient.
Patients were censored at the time of their first events. LV mass
index was analyzed in several ways. First, the HR, was assessed using
LV mass as a continuous variable; then, the HRs for patients with LV
hypertrophy were compared with those of patients without hypertro-
phy; finally, to assess the prognostic effect of the ASE/EAE proposed
classification scheme, the risk for adverse clinical outcomes was as-
sessed among subjects in the four sex-specific proposed categories
of indexed LV mass. For this purpose, we investigated whether the
risk for adverse events differed among ASE/EAE categories using dif-
ferent multivariate statistical models: multiple-category models, in
which the risk for adverse outcome in each category was compared
with that associated with normal indexed LV mass, which served as
the reference group (HR, 1), and trend models, in which we investi-
gated whether there was a stepwise increase in the risk for adverse
outcomes from one category to the next higher one.
Multivariate analyses included the following covariates: age (years),
gender, atrial fibrillation, LV ejection fraction, WMSI, and significant
valvular disease. Ancillary analyses were performed in the subgroup
of patients in whom information on risk factors was available, and
these covariates were added to the multivariate model. Finally, we
tested for interactions between gender and LV hypertrophy grade
and between cardiac rhythm and LV hypertrophy grade.
All tests were two tailed. P values < .05 were considered statisti-
cally significant. All analyses were performed using SPSS version
15.0 for Windows (SPSS, Inc., Chicago, IL).RESULTS
During the study period, 2,545 subjects (mean age, 61.9615.8 years;
56.3%women) met the inclusion criteria andwere considered for the
analysis. The mean LV mass indexed to BSA was 107.5 6 37.3 g/m2
among all subjects enrolled. According to the ASE/EAE guideline cut-
offs for LVmass/BSA, 1,198 patients (47.1%) were classified as having
LV hypertrophy, and 1,347 (52.9%) had normal LV mass indexes. LV
hypertrophy was mild in 391 patients (15.4%), moderate in 307
(12.1%), and severe in 500 (19.6%). Patients with higher categories
of indexed LV mass were older, had higher body mass indexes, and
were more likely to be women and to have hypertension, diabetes
mellitus, hyperlipidemia, valvular heart disease, and atrial fibrillation,
while there was no difference in smoking status. Higher degrees of
LV hypertrophy were associated with worse systolic function and
larger left atria (Table 1).Follow-Up Data
Mortality. After a mean follow-up period of 2.5 6 1.2 years, death
occurred in 121 patients (4.8%). Greater LVmass was associated with
a linear increase in the risk for death (for each 1 g/m2 increase in LV
mass index, there was a 1.2% increase in the risk for death (HR, 1.012;
95% CI, 1.01–1.015; P < .0001), and this association remained
Table 1 Baseline clinical and echocardiographic characteristics according to LV hypertrophy severity
Variable
Total
(n = 2,545)
No LVH
(n = 1,347)
Mild LVH
(n = 391)
Moderate LVH
(n = 307)
Severe LVH
(n = 500) P for trend
Baseline clinical characteristics
Age (y) 61.9 6 15.8 67.6 6 16.5 64.9 6 14.3 66.3 6 13.0 68.6 6 12.9 <.001
Women 1434 (56.3%) 725 (53.8%) 209 (53.5%) 176 (57.3%) 324 (64.8%) <.001
BSA (m2) 1.82 6 0.22 1.83 6 0.22 1.82 6 0.21 1.83 6 0.22 1.78 6 0.20 <.001
BMI (m/kg2) 26.2 6 4.6 25.4 6 4.6 27.1 6 4.4 26.6 6 4.3 27.2 6 4.6 <.001
Hypertension (n = 1,851) 1325 (71.6%) 553 (60.2%) 236 (80.0%) 193 (80.8%) 343 (86.2%) <.001
Diabetes mellitus (n = 1,851) 228 (12.3%) 92 (10.0%) 36 (12.2%) 37 (15.5%) 63 (15.8%) .001
Hyperlipidemia (n = 1,850) 444 (24.0%) 194 (21.1%) 77 (26.1%) 60 (25.1%) 113 (28.4%) .004
Smoking status (n = 1,851) 187 (10.1%) 100 (10.9%) 29 (9.8%) 23 (9.6%) 35 (8.8%) .154
Prior acute coronary syndromes 230 (9.0%) 98 (7.3%) 42 (10.7%) 27 (8.8%) 63 (12.6%) .001
History of chronic/stable coronary artery disease 309 (12.1%) 125 (9.3%) 46 (11.8%) 51 (16.6%) 87 (17.4%) <.001
History of heart failure 208 (8.2%) 75 (5.6%) 35 (9.0%) 35 (11.4%) 63 (12.6%) <.001
Prior stroke 42 (1.7%) 17 (1.3%) 3 (0.8%) 7 (2.3%) 15 (3.0%) .007
Significant valvular heart disease 274 (10.8%) 72 (5.3%) 42 (10.7%) 44 (14.3%) 116 (23.2%) <.001
Atrial fibrillation 196 (7.7%) 76 (5.6%) 32 (8.2%) 27 (8.8%) 61 (12.2%) <.001
Echocardiographic characteristics
LVEF (%) 64.6 6 12.2 66.1 6 10.5 64.0 6 12.0 64.0 6 12.7 61.6 6 15.2 <.001
WMSI 1.07 6 0.24 1.03 6 0.14 1.06 6 0.21 1.09 6 0.28 1.18 6 0.39 <.001
LAVI (mL/m2) (n = 1,624) 34.7 6 17.0 29.4 6 13.5 36.0 6 16.7 36.2 6 15.7 46.7 6 19.7 <.001
Normal diastolic function 545 (21.4%) 366 (27.2%) 75 (19.2%) 49 (16.0%) 55 (11.0%) <.001
Grade I diastolic dysfunction 411 (16.1%) 155 (11.5%) 77 (19.7%) 70 (22.8%) 109 (21.8%) <.001
Grade II diastolic dysfunction 504 (19.8%) 233 (17.3%) 94 (24.0%) 64 (20.8%) 113 (22.6%) <.001
Grade III or IV diastolic dysfunction 32 (1.3%) 11 (0.8%) 3 (0.8%) 7 (2.3 %) 11 (2.2 %) <.001
Undetermined diastolic dysfunction 1053 (41.4%) 582 (43.2%) 142 (36.3 %) 117 (38.1%) 212 (42.4%) <.001
RWT > 0.42 1007 (39.6%) 321 (23.8%) 193 (49.4%) 169 (55.0%) 324 (64.8%) <.001
Medications 440 (17.3%) 231 (17.1%) 69 (17.6%) 50 (16.3%) 90 (18.0%) .796
Antiplatelet agents 469 (18.4%) 250 (18.6%) 75 (19.2%) 48 (15.6%) 96 (19.2%) .911
b-blockers 333 (13.1%) 156 (11.6%) 54 (13.8%) 37 (12.1%) 86 (17.2%) .004
Diuretics 262 (10.3%) 140 (10.4%) 35 (9.0%) 34 (11.1%) 53 (10.6%) .823
Calcium channel blockers 741 (29.1%) 379 (28.1%) 114 (29.2%) 91 (29.6%) 157 (31.4%) .170
ACE inhibitors/ARBs 327 (12.8%) 174 (12.9%) 52 (13.3%) 41 (13.4%) 60 (12.0%) .698
Statins 2 (0.1%) 1 (0.1%) 0 0 1 (0.2%) .543
Antiarrhythmic agents (class IA, IB) 26 (1.0%) 17 (1.3%) 3 (0.8%) 2 (0.7%) 4 (0.8%) .278
Antiarrhythmic agents (class IC) 18 (0.7%) 11 (0.8%) 2 (0.5%) 2 (0.7%) 3 (0.6%) .592
Amiodarone 117 (4.6%) 60 (4.5%) 20 (5.1%) 13 (4.2%) 24 (4.8%) .823
Insulin/oral hypoglycemic drugs 174 (6.8%) 87 (6.5%) 21 (5.4%) 18 (5.9%) 48 (9.6%) .051
Anticoagulants 440 (17.3%) 231 (17.1%) 69 (17.6%) 50 (16.3%) 90 (18.0%) .796
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; LAVI, left atrial volume index; LVH, LV hypertro-
phy; LVEF, LV ejection fraction.
Data are expressed as mean 6 SD or as number (percentage). Unless otherwise specified, data were obtained for all 2,545 patients.
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brillation, LVejection fraction, WMSI, and significant valvular disease
(adjusted HR, 1.007; 95% CI, 1.003–1.011; P < .0001). Patients with
LV hypertrophy had significantly worse survival. Throughout the
follow-up period, the presence of LV hypertrophy conferred a three-
fold increased risk for death (HR, 3.1; 95% CI, 2.07-4.65; P < .0001),
which remained significant after multivariate adjustment for age, gen-
der, atrial fibrillation, LV ejection fraction, WMSI, and significant val-
vular disease (adjusted HR, 2.14; 95% CI, 1.39–3.29; P = .001).
There was a strong graded association between the severity of LV hy-
pertrophy and survival (P< .0001; Figure 1). At 3 years, Kaplan-Maier
estimated survival was 97.4 6 0.5% in patients with normal LV mass
and 94.361.5% in those with mild, 91.56 2.0% in those with mod-
erate, and 90.9 6 1.5% in those with severe LV hypertrophy.
Compared with patients with normal LV mass, the risk for deathwas greater than twofold in patients with mild LV hypertrophy (HR,
2.17; 95% CI, 1.23–3.81; P = .007), greater than threefold in those
with moderate LV hypertrophy (HR, 3.04; 95% CI, 1.76–5.23; P <
.0001), and almost fourfold increased in those with severe LV hyper-
trophy (HR, 3.81 95% CI, 2.43–5.97; P < .0001) (Table 2). After ad-
justing for age, gender, atrial fibrillation, LV ejection fraction, WMSI,
and significant valvular disease, the strong association between LV
hypertrophy severity grade and death remained significant (for mild
LV hypertrophy: adjusted HR, 1.81; 95% CI, 1.03–3.20; P = .040;
for moderate LV hypertrophy: adjusted HR, 2.31; 95% CI, 1.33–
4.01; P = .003; and for severe LV hypertrophy: adjusted HR, 2.30;
95% CI, 1.39–3.79; P < .0001 compared with normal LV mass)
(Table 2). When RWT was added to this multivariate model, the re-
sults were similar (for mild LV hypertrophy: adjusted HR, 1.63;
95%CI, 0.91–2.91; P = .099; for moderate LV hypertrophy: adjusted
Figure 1 Overall mortality according to the ASE/EAE proposed
classification scheme. The black line indicates patients without
LV hypertrophy, the green line those with mild hypertrophy,
the orange line those with moderate hypertrophy, and the red
line those with severe hypertrophy.
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Barbieri et al 1387HR, 2.01; 95% CI, 1.13–3.57; P = .017; and for severe LV hypertro-
phy: adjusted HR, 1.92; 95% CI, 1.13–3.28; P = .016 compared
with normal LV mass).
After further adjustment for history of acute coronary syndromes,
history of chronic coronary artery disease, history of heart failure, and
prior stroke, the association between LV mass partition values and
death remained significant (for mild LV hypertrophy: HR, 1.73;
95% CI, 0.98–3.06; P = .059; for moderate LV hypertrophy: HR,
2.16; 95% CI, 1.24–3.76; P = .007; and for severe LV hypertrophy:
HR, 2.15; 95% CI, 1.31–3.54; P = .003). After further adjustment
for cardiovascular risk factors (hypertension, diabetes mellitus, hyper-
lipidemia, and smoking) the association between LV hypertrophy se-
verity and overall death persisted (for mild LV hypertrophy: adjusted
HR, 1.77; 95% CI, 0.91–3.46; P = .092; for moderate LV hypertro-
phy: adjusted HR, 2.47; 95% CI, 1.31–4.67; P = .005; and for severe
LV hypertrophy: adjusted HR, 2.15; 95% CI, 1.19–3.89; P = .011
compared to normal). Furthermore, after adjusting for medications,
the results were similar (data not shown). In the subgroup of patients
in whomdiastolic function wasmeasurable, this variable was added to
the multivariate model, and LV mass remained associated with death.
Using trend models, there was a 50% increase in hazard for death
per increase in category of LV hypertrophy (HR, 1.54; 95% CI, 1.34–
1.77; P < .0001). On multivariate analysis, the adjusted HR was 1.31
(95% CI, 1.12–1.53; P = .001).
Cardiovascular Morbidity. During the follow-up period, 295 pa-
tients (11.6%) were hospitalized for cardiovascular disease. Indexed
LV mass was associated with an increased risk for cardiovascular hos-
pitalization; for each 1 g/m2 increase in LV mass index, the HR was
1.010 (95% CI, 1.008–1.013; P < .0001), and this association
persisted onmultivariate analysis adjusting for age, gender, atrial fibril-
lation, LVejection fraction, WMSI, and significant valvular disease (ad-
justed HR, 1.006; 95% CI, 1.003–1.009; P = .001). Accordingly, therisk for hospitalization for cardiovascular diseases was significantly
higher in patients with LV hypertrophy (HR, 2.58; 95% CI,
2.02–3.31; P < .001) compared with those with normal LV mass.
This association remained significant after multivariate adjustment
for age, gender, atrial fibrillation, LV ejection fraction, WMSI, and
significant valvular disease (adjusted HR, 1.88; 95% CI, 1.44–2.45;
P < .0001).
There was a significant risk gradient for cardiovascular morbidity
across the degrees of LV hypertrophy (Figure 2). At 3 years, the
Kaplan-Maier estimated cumulative incidence of hospitalizations
for cardiovascular disease was 7.7% in patients with normal, 11.0%
in those with mildly abnormal, 18.1% in those with moderately ab-
normal, and 24.2% in those with severely abnormal LV mass (P <
.0001). Table 3 shows the reasons for the first hospital admission:
patients with more severe LV hypertrophy were more likely to be
admitted for heart failure and atrial fibrillation but also ST-segment
elevation myocardial infarction and lower limb critical ischemia. In
multiple-category models, patients with greater LV mass had a higher
incidence of hospitalization for cardiovascular diseases (compared
with the reference group with normal LV mass) (for mild LV hyper-
trophy: HR, 1.47; 95% CI, 1.00–2.15; P = .048; for moderate LV
hypertrophy: HR, 2.50; 95% CI, 1.77–3.54; P < .001; and for se-
vere LV hypertrophy: HR, 3.48; 95% CI, 2.65–4.59; P < .0001)
(Table 2).
On multivariate analysis, after adjustment for age, gender, atrial fi-
brillation, LVejection fraction, WMSI, and significant valvular disease,
this graded association between LV mass category and cumulative in-
cidence of cardiovascular hospitalizations remained strong (for mild
LV hypertrophy: adjusted HR, 1.24; 95% CI, 0.84–1.82; P = .277;
for moderate LV hypertrophy: adjusted HR, 2.02; 95% CI, 1.42–
2.88; P < .0001; and for severe LV hypertrophy: adjusted HR,
2.38; 95% CI, 1.75–3.23, P < .0001) (Table 2). When RWT was
added to this multivariate model, the results were similar (for mild
LV hypertrophy: adjusted HR, 1.28; 95% CI, 0.84–1.93; P = .24;
for moderate LV hypertrophy: adjusted HR, 1.77; 95% CI, 1.17–
2.67, P = .007; and for severe LV hypertrophy: adjusted HR, 2.28;
95% CI, 1.59–3.27, P < .001 compared with normal LV mass).
After further adjustment for history of acute coronary syndromes, his-
tory of chronic coronary artery disease, history of heart failure, and
prior stroke, the association between LVmass partition values and car-
diovascular morbidity remained significant (for mild LV hypertrophy:
HR, 1.23; 95% CI, 0.82–1.85, P = .323; for moderate LV hypertro-
phy: HR, 1.60; 95%CI, 1.08–2.39; P= .021; and for severe LV hyper-
trophy: HR, 2.07; 95%CI, 1.48–2.88; P < .001). After adding the risk
factors to the multivariate model, the graded association persisted (for
mildly abnormal LVmass: adjusted HR, 0.98; 95%CI, 0.65–1.49; P=
.929; for moderately abnormal LV mass: adjusted HR, 1.73; 95% CI,
1.20–2.50; P = .003; and for severely abnormal LV mass: adjusted
HR, 1.84; 95% CI, 1.33–2.55; P < .0001).
After adjusting for medications, the results were unchanged (data
not shown).
Using trend models, there was a 43% increase in the hazard for
hospitalization for cardiovascular disease per increase in category of
LV hypertrophy (HR, 1.43; 95% CI, 1.16–1.44, P < .0001). This asso-
ciation was maintained on multivariate analysis; the HR was 1.29
(95% CI, 1.12–1.53; P = .001) per increase in category of LV hyper-
trophy. In the subgroup of patients in whom diastolic function was
measurable, this variable was added to the multivariate model, and
LV mass maintained its association with cardiovascular morbidity.
Further testing for interaction for gender and cardiac rhythm was
not significant (all P values > .10).
Table 2 Univariate and multivariate Cox regression analysis for death and cardiovascular hospitalizations
Variable Unadjusted HR 95% CI P Adjusted HR* 95% CI P
Death
Mass/BSA
1 1
Mild 2.17 1.23–3.81 .007 1.81 1.03–3.20 .041
Moderate 3.04 1.76–5.23 <.001 2.31 1.33–4.01 .003
Severe 3.81 2.43–5.97 <.001 2.30 1.39–3.79 .001
Mass/height
Normal 1 1
Mild 1.45 0.83–2.54 .187 1.18 0.67–2.07 .563
Moderate 2.62 1.54–4.44 <.001 1.97 1.15–3.37 .013
Severe 2.33 1.50–3.61 <.001 1.52 0.95–2.42 .079
Mass/height2.7
1 1
Mild 1.95 1.12–3.38 .017 1.58 0.90–2.76 .110
Moderate 2.25 1.30–3.91 .004 1.73 0.99–3.02 .056
Severe 2.93 1.85–4.63 .000 1.88 1.16–3.05 .010
Cardiovascular hospitalizations
Mass/BSA
1 1
Mild 1.47 1.00–2.15 .048 1.24 0.84–1.82 .277
Moderate 2.50 1.77–3.54 <.001 2.02 1.42–2.88 .001
Severe 3.48 2.65–4.59 <.001 2.38 1.75–3.22 <.001
Mass/height
Normal 1 1 .003
Mild 1.73 1.19–2.50 .004 1.49 1.02–2.16 .039
Moderate 2.50 1.71–3.64 <.001 2.01 1.38–2.95 <.001
Severe 2.12 1.54–2.90 <.001 1.52 1.09–2.12 .013
Mass/height2.7
1 1
Mild 1.72 1.18–2.52 .005 1.53 1.04–2.25 .031
Moderate 2.55 1.78–3.65 <.001 2.09 1.45–3.01 <.001
Severe 2.15 1.55–2.98 <.001 1.50 1.06–2.11 .021
*Multivariate adjustment for age, sex, atrial fibrillation, LV ejection fraction, WMSI, and greater than moderate valvular disease.
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subjects, the mean LV mass indexed to height was 117.96 42.2 g/m,
and the mean LV mass indexed to height2.7 was 50.1 618.5 g/m2.7.
Applying the ASE/EAE partition values10 for mass indexed to height,
1,231 patients (48.4%) had normal LV mass, 429 (16.9%) had mild
LV hypertrophy, 295 (11.6%) had moderate LV hypertrophy, and
590 (23.2%) had severe LV hypertrophy. Applying the ASE/EAE par-
tition values10 for LV mass indexed to height2.7, 1,147 patients
(45.1%) had normal LV mass, 442 (17.4%) had mild LV hypertrophy,
367 (14.4%) hadmoderate LV hypertrophy, and 589 (32.1%) had se-
vere LV hypertrophy. Similarly to LV mass/BSA, the partition values
for LV mass/height and LV mass/height2.7 were associated with a sig-
nificant and graded increased risk for death and cardiovascular hospi-
talizations; such associations remained significant on multivariate
analyses adjusting for age, gender, atrial fibrillation, LV ejection frac-
tion, WMSI, and significant valvular disease (Table 2).LV Geometry
In our population, 40% of patients had normal geometry, 13% had
concentric remodeling, 27% had eccentric hypertrophy, and 20%
had concentric hypertrophy. LV concentric and eccentric hypertro-
phy were associated with death (HR, 3.47; 95% CI, 2.14–5.62,P < .001; and HR, 2.96; 95% CI, 1.77–4.97; P < .001) and cardiovas-
cular hospitalizations (HR, 1.95; 95% CI, 1.39–2.73; P < .001; and
HR, 2.86; 95% CI, 2.06–3.99; P < .001), while concentric remodel-
ing was not (HR, 1.22; 95% CI, 0.55 to 2.71; P = .630 for death; and
HR, 1.24; 95% CI, 0.76–2.02; P = .385). Results were similar on
multivariate analysis (data not shown). Thus, the main determinant
of prognosis was the presence of LV hypertrophy rather than the
type of remodeling.DISCUSSION
To date, three approaches have been used for the definition of cutoff
values to categorize echocardiographic parameters10: (1) the method
most widely used is statistical, based on standard deviations above
and below the reference limits (mean values) or on percentiles ob-
tained from a group of apparently healthy individuals; (2) values cat-
egorized according to cardiovascular outcomes on follow-up,
whereby limits are identified that indicate increasing risk with increas-
ing grade of deviation; and (3) choice of cutoffs on the basis of expert
opinion. To comply with the need to standardize echocardiographic
measures,22 in 2005, the ASE and EAE proposed categories for the
description of values exceeding the reference intervals.10
Figure 2 Cumulative incidence of hospitalizations for cardio-
vascular disease according to the ASE/EAE proposed classifi-
cation scheme. The black line indicates patients without LV
hypertrophy, the green line those with mild hypertrophy, the
orange line those with moderate hypertrophy, and the red line
those with severe hypertrophy.
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calculated LV mass using LV linear dimensions indexed to BSA,
were obtained from the distribution in relation to reference limits in
a ethnically heterogeneous North American population of 510 white,
African American, and American Indian adults (the first method).11
Recently, percentile-derived values from a large-scale, population-
based study in apparently healthy individuals as well as those with
prevalent disease of 5,000 mid-Europeans revealed comparable cut-
off values.23 Ideally, to provide normative data about the degree to
which echocardiographic LV hypertrophy measurements deviate
from normal, a practical approach that predicts outcomes or prognosis
would be preferred. However, to the best of our knowledge, whether
the ASE/EAE categorization of LV hypertrophy is able to predict prog-
nosis in clinical practice has never been evaluated. Therefore, the ra-
tionale of the current investigation was to provide the first systematic
external documentation (clinical validation by application). The longi-
tudinal design of the present study facilitated this type of validation.
We analyzed a broad sample of elective adult outpatients that in-
cluded healthy and diseased individuals. Our data showed that echo-
cardiographically detected LVmass and the partition values proposed
by the ASE and EAEwere strongly related to death and cardiovascular
morbidity and were able to classify a risk gradient. The greater the
grade of LV hypertrophy severity, the worse the prognosis. Results
of trend models indicated an adjusted stepwise increase in hazard
per category increase in LV hypertrophy of about 30% for both death
and cardiovascular morbidity. The incremental adverse impact associ-
atedwithmild,moderate, and severe LV hypertrophy (comparedwith
normal reference range) persisted in multivariate analyses adjusting
for the effect of other known predictors and was generally consistent
within the various statistical models explored.
LV hypertrophy is related to a vast number of identifiable condi-
tions, including advanced age, hypertension, obesity, diabetes, priormyocardial infarction, and valvular heart disease. In addition, several
other risk factors (unmeasured in our study), including sodium intake,
neurohumoral influences, insulin, other growth factors and genetic
risk factors, may be involved in modulating a complex trait such as
the development and pattern of LV hypertrophy.
Although considerable interest exists in recognizing putative risk
factors that modulate LV hypertrophy, the research in this topic re-
mains scarce, with insufficient clinical data. Therefore, the mecha-
nisms responsible for LV mass increase remain elusive and are
beyond the scope of this study.24
We can speculate that increased LV mass is a marker of global
cardiovascular risk burden because it reflects and integrates the
long-term level of activity of factors inducing progression of athero-
sclerosis.25 Beyond traditional risk factors, there may be others
(unmeasured in our report), including biologic factors and hemody-
namic (such as arterial stiffness) and nonhemodynamic (i.e., insulin
and insulin growth factors) factors that are able to contemporane-
ously induce LV hypertrophy and progression or destabilization of
atherosclerotic lesions. On the other hand, LV hypertrophy may
represent a mediator of myocardial ischemia, with potential evolution
toward arrhythmias and heart failure.
Our data confirmed26 that echocardiographic LV hypertrophy
identified a population at high risk for cardiovascular disease.
Subjects with more severe grades of LV hypertrophy were older
and more likely to have hypertension and diabetes. These factors, as-
sociated with LV hypertrophy, are atherogenic. Therefore, LV mass
may be considered as an integrated marker of atherosclerosis and
absolute cardiovascular risk.23 Accordingly, the present study demon-
strated a relationship between LV hypertrophy grade and incident
hospitalizations for lower limb critical ischemia. Nevertheless, in our
population, echocardiographic LV hypertrophy independently pre-
dicted an increased risk for death and cardiovascular morbidity after
adjustment for other major risk factors. Therefore, increased LV mass
may also represent a direct causative factor for events; in particular,
LV hypertrophy may mediate myocardial ischemia, with potential
evolution toward heart failure and arrhythmias. Notably, the present
study, documenting a significant increased risk for hospitalizations for
heart failure per category of LV mass, corroborates the hypothesis
of LV hypertrophy as a mediator of cardiovascular events.
Unfortunately, in clinical practice, it is generally impossible to establish
a link between LV hypertrophy and one or more potential causative
factors in individual patients.23
Analyses from the Framingham Heart Study27 and elsewhere28-30
have unequivocally demonstrated the prognostic value of
echocardiographically detected LV hypertrophy as a continuous
measure to predict cardiovascular disease events and survival. Our
study confirmed these findings by showing that a greater indexed LV
mass as a continuous variable was associated with an increasing risk
for death and cardiovascular morbidity.1
Our study expands these findings to the categories of LV hypertro-
phy. In clinical practice, the measures obtained at the echocardio-
graphic exam must be interpreted and qualified such that the exam is
informative and useful for nonspecialists.22 To this end, the ASE/EAE
classificationwas created to enhance the comprehensibility ofmeasure-
ments to clinicians and to promote uniformity in describing measure-
ments. Our study validated such a categorization scheme in relation
to long-term prognosis in a large group of unselected subjects referred
for echocardiography. LV mass partition values were able to classify
a risk gradient regardless of indexation to BSA, height, or height2.7.
Only the study of Vasan et al.2 subdivided on an ordinal scale the
values exceeding reference limits for practical use by clinicians.
Table 3 Causes of incident hospitalizations for cardiovascular disease
Variable Total No LVH Mild LVH Moderate LVH Severe LVH P for trend
STEMI 13 (0.5%) 4 (0.3%) 1 (0.3%) 0 8 (1.6%) .005
UA-NSTEMI 38 (1.5%) 17 (1.3%) 9 (2.3%) 8 (2.6%) 4 (0.8%) .956
Stable angina 15 (0.6%) 7 (0.3%) 3 (0.8%) 3 (1.0%) 2 (0.4%) .959
Coronary artery disease 31 (1.2%) 12 (0.9%) 7 (1.8%) 6 (2.0%) 6 (1.2%) .328
Atrial fibrillation 48 (1.9%) 20 (1.5%) 5 (1.3%) 10 (3.3%) 13 (2.6%) .042
Ventricular arrhythmias 5 (0.2%) 2 (0.1%) 2 (0.5%) 0 1 (0.2%) .977
Heart failure 80 (3.1%) 24 (1.8%) 13 (3.3%) 8 (2.6%) 35 (7.0%) <.001
Stroke/TIA 26 (1.0%) 11 (0.8%) 4 (1.0%) 6 (2.0%) 5 (1.0%) .374
Lower limb critical ischemia 41 (1.6%) 16 (1.2%) 3 (0.8%) 11 (3.6%) 11 (2.2%) .020
LVH, LV hypertrophy; NSTEMI, non–ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; TIA,
transient ischemic attack; UA, unstable angina.
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a broad sample (n = 4,957) and classified the measurements accord-
ing to increasing deviation from the height-specific and sex-specific
reference limits and the 95th, 98th, and 99th percentile values for
the broad sample. To validate this categorization scheme, they used
multivariate proportional-hazards regression to assess the relations
of LV mass categories to risk for cardiovascular events and found
a 1.3-fold adjusted risk for cardiovascular disease events per category
of LV mass, which is almost identical to what we found in the present
study using trend models.
Limitations and Strengths
The study population was referral based, and the extent to which the
data can be generalized to other populations remains unknown. In
particular, because the vast majority of subjects enrolled were
Caucasian, results may not be applicable to other ethnicities.
Information on risk factors was retrievable for only 73% of the
patients. For this reason, multivariate analysis including risk factors
as covariates was performed separately as ancillary analysis.
The use of linear dimensions for LV mass determination presents
potential limitations. Linear measurements are based on the assump-
tion that the left ventricle is represented by a prolate ellipse, while car-
diac disease may result in distorted LV geometry with the possibility of
underestimating or overestimating LV mass.10 Furthermore, cubing
linear dimensions within the formula can multiply even small errors.
However, LVmass obtained with this method has been well validated
by necropsy.21
It is possible for a patient to shift between categories simply on the
basis of limitations in the reproducibility of echocardiographic mea-
surements.31 However, linear dimensions can be obtained from either
2D-guided M-mode images or directly from correctly aligned 2D
images with reasonable agreement32 and good reproducibility.33
Particularly, the latter method overcomes the common problem of
oblique parasternal images that result in overestimation of cavity by
M-mode imaging.31
We acknowledge that there are some limitations using hospital dis-
charge International Classification of Disease, Ninth Revision, Clinical
Modification codes as the basis for a definition of cardiovascular mor-
bidity, because it does not equate to the stringent criteria used, for ex-
ample, in the Framingham study, with a risk for misclassification.1
However, this setting provided an opportunity to collect follow-up in-
formation in 100% of the patients by passive surveillance through the
province inpatient medical records. Therefore, despite difficulties in
the interpretation of administrative hospital data, hospital admissionsinvolving diagnoses of cardiovascular disease can provide valuable
information about the incidence of cardiovascular complications in
patients with LV hypertrophy.
Other three-dimensional techniques such as magnetic resonance
imaging would have provided greater accuracy and reproducibility,
but this is beyond the scope of the study, and B-mode echocardiogra-
phy is at present the best method for screening large populations.
Finally, although we have demonstrated significant prognostic
value of this categorization scheme, the therapeutic implications of
this classification, if any, are unknown.
Strengths of the study include the real-time contemporary mea-
surement of LV mass in a large number of unselected outpatients
and completeness of follow-up.CONCLUSIONS
In a large population of unselected outpatients, we demonstrated the
ability of the classification scheme of LV hypertrophy proposed by the
ASE and EAE to predict mortality and cardiovascular morbidity. This
considerably enhances its utility for clinicians and may improve com-
munication among laboratories.REFERENCES
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